S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:HZNP

Horizon Therapeutics Public - HZNP News Headlines

$67.12
-2.53 (-3.63%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$66.60
$70.23
50-Day Range
$66.96
$92.39
52-Week Range
$60.76
$120.54
Volume
3.02 million shs
Average Volume
2.06 million shs
Market Capitalization
$15.46 billion
P/E Ratio
20.72
Dividend Yield
N/A
Price Target
$117.22
Get Horizon Therapeutics Public News Delivered to You Automatically

Sign up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

HZNP Media Mentions By Week

HZNP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HZNP
News Sentiment

-0.25

0.32

Average
Medical
News Sentiment

HZNP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HZNP Articles
This Week

31

2

HZNP Articles
Average Week



SourceHeadline
marketbeat.com logoHorizon Therapeutics Public Limited (NASDAQ:HZNP) EVP Sean M. Clayton Buys 745 Shares
marketbeat.com - August 8 at 7:03 PM
marketbeat.com logoHorizon Therapeutics Public Limited (NASDAQ:HZNP) Expected to Post Q3 2022 Earnings of $1.30 Per Share
marketbeat.com - August 8 at 2:15 AM
marketbeat.com logoStockNews.com Lowers Horizon Therapeutics Public (NASDAQ:HZNP) to Hold
marketbeat.com - August 5 at 11:20 PM
MarketBeat logoHorizon Therapeutics Public (NASDAQ:HZNP) Rating Lowered to Hold at StockNews.com
americanbankingnews.com - August 9 at 3:02 AM
MarketBeat logoHorizon Therapeutics Public Limited to Post Q3 2022 Earnings of $1.30 Per Share, Oppenheimer Forecasts (NASDAQ:HZNP)
americanbankingnews.com - August 9 at 1:56 AM
MarketBeat logoHorizon Therapeutics Public (NASDAQ:HZNP) Downgraded by SVB Leerink
americanbankingnews.com - August 8 at 5:23 AM
MarketBeat logoThe Goldman Sachs Group Cuts Horizon Therapeutics Public (NASDAQ:HZNP) Price Target to $144.00
americanbankingnews.com - August 7 at 7:48 AM
MarketBeat logoBMO Capital Markets Cuts Horizon Therapeutics Public (NASDAQ:HZNP) Price Target to $117.00
americanbankingnews.com - August 7 at 7:48 AM
MarketBeat logoHorizon Therapeutics Public (NASDAQ:HZNP) Sees Strong Trading Volume
americanbankingnews.com - August 6 at 6:38 AM
MarketBeat logoHorizon Therapeutics Public (NASDAQ:HZNP) Price Target Cut to $90.00
americanbankingnews.com - August 6 at 5:52 AM
MarketBeat logoHorizon Therapeutics Public (NASDAQ:HZNP) Hits New 1-Year Low Following Weak Earnings
americanbankingnews.com - August 5 at 4:24 AM
msn.com logoHorizon Therapeutics: Q2 Earnings Insights
msn.com - August 3 at 6:00 PM
seekingalpha.com logoHorizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 12:59 PM
finance.yahoo.com logoHorizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
finance.yahoo.com - August 3 at 7:59 AM
MarketBeat logoHorizon Therapeutics Public Limited (NASDAQ:HZNP) Receives $133.10 Consensus PT from Analysts
americanbankingnews.com - August 2 at 4:55 AM
MarketBeat logoHorizon Therapeutics Public (HZNP) to Release Earnings on Wednesday
americanbankingnews.com - August 2 at 2:28 AM
finance.yahoo.com logoHorizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
finance.yahoo.com - July 21 at 9:43 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Horizon Therapeutics (HZNP) Stock?
finance.yahoo.com - July 14 at 5:08 PM
finance.yahoo.com logoHorizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
finance.yahoo.com - July 11 at 10:05 AM
forbes.com logoHorizon Therapeutics Public Limited Company (HZNP)
forbes.com - July 8 at 8:59 AM
finance.yahoo.com logoFDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
finance.yahoo.com - July 8 at 8:59 AM
finance.yahoo.com logoHorizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
finance.yahoo.com - July 7 at 8:44 AM
finance.yahoo.com logoHorizon Therapeutics (NASDAQ:HZNP) delivers shareholders massive 48% CAGR over 5 years, surging 3.2% in the last week alone
finance.yahoo.com - June 27 at 9:33 AM
finance.yahoo.com logoNew Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
finance.yahoo.com - June 24 at 3:25 PM
seekingalpha.com logoHorizon Therapeutics submits regulatory filing for approval of Uplizna in Brazil
seekingalpha.com - June 15 at 1:40 PM
finance.yahoo.com logoHorizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
finance.yahoo.com - June 15 at 8:38 AM
finance.yahoo.com logoHorizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
finance.yahoo.com - June 15 at 8:38 AM
seekingalpha.com logoHorizon Therapeutics initiated Buy at UBS ahead of key readout
seekingalpha.com - June 14 at 10:35 PM
markets.businessinsider.com logoAnalyst Ratings for Horizon Therapeutics
markets.businessinsider.com - June 14 at 5:35 PM
finance.yahoo.com logoAnalysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
finance.yahoo.com - June 11 at 11:51 AM
finance.yahoo.com logoHorizon Therapeutics plc Named a Top Company for Executive Women
finance.yahoo.com - June 9 at 1:21 PM
finance.yahoo.com logoHorizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
finance.yahoo.com - June 6 at 4:55 PM
finance.yahoo.com logoHorizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
finance.yahoo.com - June 2 at 12:33 PM
finance.yahoo.com logoData Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
finance.yahoo.com - June 1 at 11:30 AM
finance.yahoo.com logoAnalysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
finance.yahoo.com - May 31 at 10:24 AM
finance.yahoo.com logoHorizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
finance.yahoo.com - May 24 at 10:07 AM
msn.com logoHorizon Therapeutics Earnings Perspective: Return On Capital Employed
msn.com - May 19 at 8:57 PM
finance.yahoo.com logoHorizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
finance.yahoo.com - May 11 at 8:37 AM
finance.yahoo.com logoHorizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
finance.yahoo.com - May 9 at 5:13 PM
finance.yahoo.com logoHorizon Therapeutics Public Limited Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
finance.yahoo.com - May 7 at 12:43 PM
finance.yahoo.com logoHZNP or TECH: Which Is the Better Value Stock Right Now?
finance.yahoo.com - May 4 at 12:04 PM
finance.yahoo.com logoHorizon Therapeutics plc Reports First-Quarter 2022 Financial Results
finance.yahoo.com - May 4 at 12:04 PM
seekingalpha.com logoHorizon Therapeutics says rheumatoid arthritis drug met main goal in mid-stage study
seekingalpha.com - May 3 at 10:18 AM
finance.yahoo.com logoTopline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
finance.yahoo.com - May 3 at 10:18 AM
finance.yahoo.com logoHorizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
finance.yahoo.com - May 2 at 6:41 PM
finance.yahoo.com logoHorizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
finance.yahoo.com - May 2 at 8:35 AM
finance.yahoo.com logoHorizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community
finance.yahoo.com - April 19 at 12:54 PM
finance.yahoo.com logoHorizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
finance.yahoo.com - April 18 at 3:38 PM
finance.yahoo.com logoHorizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
finance.yahoo.com - April 14 at 12:36 PM
seekingalpha.com logoHorizon Therapeutics neuromyelitis drug Uplizna effective in analysis
seekingalpha.com - April 1 at 8:09 PM
finance.yahoo.com logoNew Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
finance.yahoo.com - March 31 at 11:46 AM
finance.yahoo.com logoBiotech Stock Near Buy Point After Positive Earnings; Is It Worth Considering?
finance.yahoo.com - March 21 at 5:21 PM
finance.yahoo.com logoHorizon Therapeutics USA, Inc. -- Moody's upgrades Horizon Therapeutics to Ba1; stable outlook
finance.yahoo.com - March 18 at 10:20 AM
Get Horizon Therapeutics Public News Delivered to You Automatically

Sign up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:HZNP) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.